Skip to main content
Intermediate Technical IVT

open-label extension

A study phase where all participants receive active treatment after completing a blinded trial.

Full Definition

An open-label extension (OLE) is a study design element that allows participants who complete a randomized controlled trial to continue receiving active treatment in an unblinded fashion for an extended period. During the OLE phase, both participants and investigators know which treatment is being administered. OLEs serve multiple purposes in psychiatric research: they provide long-term safety and tolerability data, allow assessment of sustained efficacy, offer continued treatment access for participants who benefited from the study drug, and can help with patient recruitment by providing longer-term treatment options. OLE data, while valuable for safety assessment, has limitations for efficacy evaluation due to the lack of a control group and potential selection bias.

Usage

Usage note: Can be abbreviated as OLE after first use. Emphasize the unblinded nature when relevant.

In Context

  • "Patients completing the 8-week double-blind phase were eligible to enter the 44-week open-label extension." — study design description
  • "Long-term safety data from the open-label extension supported the drug's favorable benefit-risk profile." — safety conclusions

Also known as

OLE extension study open-label phase

Contrasted with

blinded phase

Don't confuse with

open-label study extension period

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON